Resource impact statement

No significant resource impact is anticipated

We do not expect this guidance to have a significant impact on resources; that is, it will be less than £5 million per year in England (or £9,100 per 100,000 population).

This is because the eligible population size is small, around 30 people, all of whom may receive treatment each year.

The company has a commercial arrangement (simple discount patient access scheme). This makes dinutuximab beta available to the NHS with a discount. The size of the discount is commercial in confidence. For enquiries about the patient access scheme contact

Dinutuximab is commissioned by NHS England. Providers are NHS hospital trusts.

This page was last updated: 22 August 2018